» Articles » PMID: 26553065

A Novel Two-step Genome Editing Strategy with CRISPR-Cas9 Provides New Insights into Telomerase Action and TERT Gene Expression

Overview
Journal Genome Biol
Specialties Biology
Genetics
Date 2015 Nov 11
PMID 26553065
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To facilitate indefinite proliferation, stem cells and most cancer cells require the activity of telomerase, which counteracts the successive shortening of telomeres caused by incomplete DNA replication at the very end of each chromosome. Human telomerase activity is often determined by the expression level of telomerase reverse transcriptase (TERT), the catalytic subunit of the ribonucleoprotein complex. The low expression level of TERT and the lack of adequate antibodies have made it difficult to study telomerase-related processes in human cells.

Results: To overcome the low CRISPR-Cas9 editing efficiency at the TERT locus, we develop a two-step "pop-in/pop-out" strategy to enrich cells that underwent homologous recombination (HR). Using this technique, we fuse an N-terminal FLAG-SNAP-tag to TERT, which allows us to reliably detect TERT in western blots, immunopurify it for biochemical analysis, and determine its subcellular localization by fluorescence microscopy. TERT co-localizes detectably with only 5-7 % of the telomeres at a time in S-phase HeLa cells; no nucleolar localization is detected. Furthermore, we extend this approach to perform single base-pair modifications in the TERT promoter; reverting a recurrent cancer-associated TERT promoter mutation in a urothelial cancer cell line results in decreased telomerase activity, indicating the mutation is causal for telomerase reactivation.

Conclusions: We develop a two-step CRISPR-Cas9 genome editing strategy to introduce precise modifications at the endogenous TERT locus in human cell lines. This method provides a useful tool for studying telomerase biology, and suggests a general approach to edit loci with low targeting efficiency and to purify and visualize low abundance proteins.

Citing Articles

A Review of Telomere Attrition in Cancer and Aging: Current Molecular Insights and Future Therapeutic Approaches.

Iskandar M, Xiao Barbero M, Jaber M, Chen R, Gomez-Guevara R, Cruz E Cancers (Basel). 2025; 17(2).

PMID: 39858038 PMC: 11764024. DOI: 10.3390/cancers17020257.


TRF1 and TRF2 form distinct shelterin subcomplexes at telomeres.

Janovic T, Perez G, Schmidt J bioRxiv. 2025; .

PMID: 39763972 PMC: 11703185. DOI: 10.1101/2024.12.23.630076.


Ubiquitin-mediated recruitment of the ATG9A-ATG2 lipid transfer complex drives clearance of phosphorylated p62 aggregates.

Broadbent D, Broadbent D, McEwan C, McEwan C, Jayatunge D, Jayatunge D Mol Biol Cell. 2024; 36(2):ar20.

PMID: 39718773 PMC: 11809316. DOI: 10.1091/mbc.E24-03-0101.


Beginning at the ends: telomere and telomere-based cancer therapeutics.

Sadr Z, Ghasemi M, Jafarpour S, Seyfi R, Ghasemi A, Boustanipour E Mol Genet Genomics. 2024; 300(1):1.

PMID: 39638969 DOI: 10.1007/s00438-024-02206-6.


Single-molecule imaging reveals the kinetics of non-homologous end-joining in living cells.

Mikhova M, Goff N, Janovic T, Heyza J, Meek K, Schmidt J Nat Commun. 2024; 15(1):10159.

PMID: 39578493 PMC: 11584804. DOI: 10.1038/s41467-024-54545-y.


References
1.
Scherer S, Davis R . Replacement of chromosome segments with altered DNA sequences constructed in vitro. Proc Natl Acad Sci U S A. 1979; 76(10):4951-5. PMC: 413056. DOI: 10.1073/pnas.76.10.4951. View

2.
Lingner J, Hughes T, Shevchenko A, Mann M, Lundblad V, Cech T . Reverse transcriptase motifs in the catalytic subunit of telomerase. Science. 1997; 276(5312):561-7. DOI: 10.1126/science.276.5312.561. View

3.
Shay J, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer. 1997; 33(5):787-91. DOI: 10.1016/S0959-8049(97)00062-2. View

4.
Kilian A, Bowtell D, Abud H, Hime G, Venter D, Keese P . Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet. 1997; 6(12):2011-9. DOI: 10.1093/hmg/6.12.2011. View

5.
Le Y, Miller J, Sauer B . GFPcre fusion vectors with enhanced expression. Anal Biochem. 1999; 270(2):334-6. DOI: 10.1006/abio.1999.4110. View